Page last updated: 2024-10-31

methylphenidate and Anxiety Neuroses

methylphenidate has been researched along with Anxiety Neuroses in 45 studies

Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.
methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.
methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.

Research Excerpts

ExcerptRelevanceReference
" Thus, a decline in state anxiety while performing a cognitive task when taking methylphenidate would discriminate between ADHD patients and controls."7.85Methylphenidate Reduces State Anxiety During a Continuous Performance Test That Distinguishes Adult ADHD Patients From Controls. ( Aviram, S; Bloch, Y; Braw, Y; Levkovitz, Y; Mimouni Bloch, A; Nitzan, U; Segev, A, 2017)
"There are controversial evidence in the literature on the role of comorbid anxiety disorders (ANX) in the improvement of attention-deficit/hyperactivity disorder (ADHD) symptoms with methylphenidate (MPH) treatment."7.75Response to methylphenidate in children and adolescents with ADHD: does comorbid anxiety disorders matters? ( Garcia, SP; Guimarães, J; Martinez, AL; Polanczyk, G; Rohde, LA; Zampieri, JF, 2009)
" Thus, a decline in state anxiety while performing a cognitive task when taking methylphenidate would discriminate between ADHD patients and controls."3.85Methylphenidate Reduces State Anxiety During a Continuous Performance Test That Distinguishes Adult ADHD Patients From Controls. ( Aviram, S; Bloch, Y; Braw, Y; Levkovitz, Y; Mimouni Bloch, A; Nitzan, U; Segev, A, 2017)
"There are controversial evidence in the literature on the role of comorbid anxiety disorders (ANX) in the improvement of attention-deficit/hyperactivity disorder (ADHD) symptoms with methylphenidate (MPH) treatment."3.75Response to methylphenidate in children and adolescents with ADHD: does comorbid anxiety disorders matters? ( Garcia, SP; Guimarães, J; Martinez, AL; Polanczyk, G; Rohde, LA; Zampieri, JF, 2009)
"Childhood narcolepsy is associated with various emotional, behavioural and cognitive dysfunctions as well as with psychiatric and neurodevelopmental disorders: anxiety, depression, attention deficit hyperactivity disorder and psychosis."1.48Childhood narcolepsy and autism spectrum disorders: four case reports. ( Dudova, I; Hrdlicka, M; Mohaplova, M; Nevsimalova, S; Prihodova, I, 2018)
"The most common comorbidities were substance use disorders (39."1.43Psychiatric Comorbidity at the Time of Diagnosis in Adults With ADHD: The CAT Study. ( Balanzá-Martínez, V; García-García, P; Piñeiro-Dieguez, B; Soler-López, B, 2016)
"In France, attention deficit disorder (ADHD) has traditionally met with two opposing approaches (biological and psychoanalytic)."1.37[Attention deficit disorder: multidisciplinary observational study over 1 year]. ( Billard, C; Chambry, J; Cohen de Lara, A; Delteil-Pinton, F; Guinard, M; Idiart, ME; Lacaze, E, 2011)
"Psychiatrists treated major depressive disorder in advanced cancer patients on the basis of the algorithm."1.35Clinical experience of the use of a pharmacological treatment algorithm for major depressive disorder in patients with advanced cancer. ( Akechi, T; Akizuki, N; Ito, T; Nakano, T; Okamura, M; Shimizu, K; Uchitomi, Y, 2008)

Research

Studies (45)

TimeframeStudies, this research(%)All Research%
pre-19906 (13.33)18.7374
1990's5 (11.11)18.2507
2000's12 (26.67)29.6817
2010's20 (44.44)24.3611
2020's2 (4.44)2.80

Authors

AuthorsStudies
Gaillard, C1
Lago, TR1
Gorka, AX1
Balderston, NL1
Fuchs, BA1
Reynolds, RC1
Grillon, C1
Ernst, M1
Boesen, K1
Paludan-Müller, AS1
Gøtzsche, PC1
Jørgensen, KJ1
Quinn, DK1
Mayer, AR1
Master, CL1
Fann, JR1
Suhaiban, H1
Javanbakht, A1
Prihodova, I1
Dudova, I1
Mohaplova, M1
Hrdlicka, M1
Nevsimalova, S1
Villas-Boas, CB1
Chierrito, D1
Fernandez-Llimos, F1
Tonin, FS1
Sanches, ACC1
Oliva, F1
Carezana, C1
Nibbio, G1
Bramante, S1
Portigliatti Pomeri, A1
Maina, G1
Bloch, Y2
Aviram, S1
Segev, A2
Nitzan, U1
Levkovitz, Y1
Braw, Y1
Mimouni Bloch, A1
Piñeiro-Dieguez, B1
Balanzá-Martínez, V1
García-García, P1
Soler-López, B1
Bottelier, MA1
Schouw, ML1
Klomp, A1
Tamminga, HG1
Schrantee, AG1
Bouziane, C1
de Ruiter, MB1
Boer, F1
Ruhé, HG1
Denys, D1
Rijsman, R1
Lindauer, RJ1
Reitsma, HB1
Geurts, HM1
Reneman, L1
Giacobini, M1
Medin, E1
Ahnemark, E1
Russo, LJ1
Carlqvist, P1
Lavretsky, H1
Reinlieb, M1
St Cyr, N1
Siddarth, P1
Ercoli, LM1
Senturk, D1
Gvirts, HZ1
Strouse, K1
Mayseless, N1
Gelbard, H1
Lewis, YD1
Barnea, Y1
Feffer, K1
Shamay-Tsoory, SG1
Mattingly, GW1
Anderson, RH1
Purper-Ouakil, D1
Garcia, SP1
Guimarães, J1
Zampieri, JF1
Martinez, AL1
Polanczyk, G1
Rohde, LA1
Warton, FL1
Howells, FM1
Russell, VA1
Gürkan, K1
Bilgiç, A1
Türkoglu, S1
Kiliç, BG1
Aysev, A1
Uslu, R1
Gadow, KD1
Nolan, EE1
Ter-Stepanian, M1
Grizenko, N1
Zappitelli, M1
Joober, R1
Gomes, KM1
Souza, RP1
Inácio, CG1
Valvassori, SS1
Réus, GZ1
Martins, MR1
Comim, CM1
Quevedo, J1
Marcus, SC1
Durkin, M1
Chambry, J1
Billard, C1
Guinard, M1
Lacaze, E1
Idiart, ME1
Delteil-Pinton, F1
Cohen de Lara, A1
Mattos, P1
Louzã, MR1
Palmini, AL1
de Oliveira, IR1
Rocha, FL1
Sánchez-Pérez, AM1
García-Avilés, Á1
Albert Gascó, H1
Sanjuán, J1
Olucha-Bordonau, FE1
Woolley, JB1
Heyman, I1
Serby, M1
ALAMANNI, V1
LING, TM1
BUCKMAN, J1
SPENCER, AM1
Janowsky, DS1
Nakane, A1
Quinn, PO1
Abikoff, H1
McGough, J1
Vitiello, B2
McCracken, J1
Davies, M2
Walkup, J1
Riddle, M1
Oatis, M1
Greenhill, L1
Skrobala, A2
March, J1
Gammon, P1
Robinson, J1
Lazell, R1
McMahon, DJ1
Ritz, L1
Okamura, M1
Akizuki, N1
Nakano, T1
Shimizu, K1
Ito, T1
Akechi, T1
Uchitomi, Y1
Posner, K1
Melvin, GA1
Murray, DW1
Gugga, SS1
Fisher, P1
Cunningham, C1
Abikoff, HB1
Ghuman, JK1
Kollins, S1
Wigal, SB1
Wigal, T1
McCracken, JT1
McGough, JJ1
Kastelic, E1
Boorady, R1
Chuang, SZ1
Swanson, JM1
Riddle, MA1
Greenhill, LL1
Bedard, AC1
Tannock, R3
Nissen, G1
Ickowicz, A1
Schachar, R1
Spencer, T2
Wilens, T1
Biederman, J2
Faraone, SV1
Ablon, JS1
Lapey, K1
Wilens, TE1
Wozniak, J1
Connor, D1
Diamond, IR1
Schachar, RJ1
Pliszka, SR1
Bojanovský, J1

Clinical Trials (10)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Cognitive vs. Emotional Psycho-Pharmacological Manipulations of Fear vs. Anxiety[NCT02153944]Phase 4142 participants (Actual)Interventional2014-06-16Completed
Effectiveness of Methylphenidate Late Formula to Reduce Cannabis Use in Young Cannabis-Related Patients and Attention Deficit Disorder Hyperactivity[NCT03481959]Phase 33 participants (Actual)Interventional2019-05-07Terminated (stopped due to insufficient recrutement in the study)
Treatments for Fathers With Attention Deficit/Hyperactivity Disorder (ADHD) and Their At-Risk Children (Fathers Too)[NCT02675400]Phase 419 participants (Actual)Interventional2015-12-31Completed
An Open International Multicentre Long-Term Follow Up Study to Evaluate Safety of Prolonged Release OROS Methlyphenidate in Adults With Attention Deficit Hyperactivity Disorder[NCT00307684]Phase 3155 participants (Actual)Interventional2006-01-31Completed
A 6-month, Open-label Extension to a 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in the Treatment of Adult Patients With Childhood-onset ADHD[NCT01338818]Phase 3299 participants (Actual)Interventional2011-04-30Completed
Real-world Evidence of Duration of Adhansia XR for Treatment of ADHD (RE-DAX): An Open-label Pragmatic Study to Assess the Real-world Effectiveness of Adhansia XR in Treatment of Adult and Adolescent Patients With ADHD in the United States[NCT04507204]Phase 4267 participants (Actual)Interventional2020-07-30Terminated (stopped due to (due to administrative reasons not related to efficacy or safety.))
Clinical and Pharmacogenetic Study of Attention Deficit With Hyperactivity Disorder (ADHD)[NCT00483106]Phase 4885 participants (Actual)Interventional1999-11-30Completed
The Effects of Methylphenidate (MPH) and Non-invasive Brain Stimulation (tDCS) on Inhibitory Control Children With Attention-Deficit/Hyperactivity Disorder (ADHD)[NCT04964427]26 participants (Actual)Interventional2021-02-08Completed
Multimodal Treatment Study of Children With ADHD[NCT00000388]Phase 40 participants Interventional1998-09-30Completed
A Randomized Controlled Trial Into the Effectiveness of a Behavioral Teacher Program Targeting ADHD Symptoms[NCT02518711]114 participants (Actual)Interventional2011-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Proportion of Correct Responses in the Working Memory Task (N-Back): Safe Condition - 1BACK - Run 1

Stimuli were presented one at a time on a screen. Participants were instructed to remember (working memory) one or three stimuli back (N-back) from the current stimulus on the screen while undergoing alternating periods of safety and threat of shock i.e. while anticipating unpleasant electric shocks or no shock (safe).Two levels of difficulties were tested: 1- and 3-back. The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually. Participants indicated whether the letter currently displayed was the same as the letter presented 1 or 3 letters back. The task included 3 runs, 8 blocks per run (4 safe and 4 threat presented alternatively), 18 sequential letters per block. Each block represented a given level of difficulty, i.e., 1- and 3-back. Performance on working memory task (n-back) accuracy was measured across condition (threat and safe) x Load (1-back, 3-back) using repeated measures ANOVA. (NCT02153944)
Timeframe: 90 minutes post drug admin plus zero seconds within a 6-hour study visit

InterventionProportion of correct responses (Mean)
fMRI: Drug Challenge With Methylphenidate0.9565625
fMRI: Drug Challenge With Placebo0.919697

Proportion of Correct Responses in the Working Memory Task (N-back): Safe Condition - 1BACK - Run 2

Stimuli were presented one at a time on a screen. Participants were instructed to remember (working memory) one or three stimuli back (N-back) from the current stimulus on the screen while undergoing alternating periods of safety and threat of shock i.e. while anticipating unpleasant electric shocks or no shock (safe). Two levels of difficulties were tested: 1- and 3-back. The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually. Participants indicated whether the letter currently displayed was the same as the letter presented 1 or 3 letters back. The task included 3 runs, 8 blocks per run (4 safe and 4 threat presented alternatively), 18 sequential letters per block. Each block represented a given level of difficulty, i.e., 1- and 3-back. Performance on working memory task (n-back) accuracy was measured across condition (threat and safe) x Load (1-back, 3-back) using repeated measures ANOVA. (NCT02153944)
Timeframe: 90 minutes plus 180 seconds within a 6-hour study visit

InterventionProportion of correct responses (Mean)
fMRI: Drug Challenge With Methylphenidate0.9529032
fMRI: Drug Challenge With Placebo0.953125

Proportion of Correct Responses in the Working Memory Task (N-back): Safe Condition - 3BACK - Run 1

Stimuli were presented one at a time on a screen. Participants were instructed to remember (working memory) one or three stimuli back (N-back) from the current stimulus on the screen while undergoing alternating periods of safety and threat of shock i.e. while anticipating unpleasant electric shocks or no shock (safe). Two levels of difficulties were tested: 1- and 3-back. The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually. Participants indicated whether the letter currently displayed was the same as the letter presented 1 or 3 letters back. The task included 3 runs, 8 blocks per run (4 safe and 4 threat presented alternatively), 18 sequential letters per block. Each block represented a given level of difficulty, i.e., 1- and 3-back. Performance on working memory task (n-back) accuracy was measured across condition (threat and safe) x Load (1-back, 3-back) using repeated measures ANOVA. (NCT02153944)
Timeframe: 90 minutes post drug admin plus 45 seconds within a 6-hour study visit

InterventionProportion of correct responses (Mean)
fMRI: Drug Challenge With Methylphenidate0.725625
fMRI: Drug Challenge With Placebo0.739697

Proportion of Correct Responses in the Working Memory Task (N-back): Safe Condition - 3BACK - Run 2

Stimuli were presented one at a time on a screen. Participants were instructed to remember (working memory) one or three stimuli back (N-back) from the current stimulus on the screen while undergoing alternating periods of safety and threat of shock i.e. while anticipating unpleasant electric shocks or no shock (safe). Two levels of difficulties were tested: 1- and 3-back. The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually. Participants indicated whether the letter currently displayed was the same as the letter presented 1 or 3 letters back. The task included 3 runs, 8 blocks per run (4 safe and 4 threat presented alternatively), 18 sequential letters per block. Each block represented a given level of difficulty, i.e., 1- and 3-back. Performance on working memory task (n-back) accuracy was measured across condition (threat and safe) x Load (1-back, 3-back) using repeated measures ANOVA. (NCT02153944)
Timeframe: 90 minutes plus 215 seconds within a 6-hour study visit

InterventionProportion of correct responses (Mean)
fMRI: Drug Challenge With Methylphenidate0.7570968
fMRI: Drug Challenge With Placebo0.7428125

Proportion of Correct Responses in the Working Memory Task (N-back): Threat Condition - 1BACK - Run 1

Stimuli were presented one at a time on a screen. Participants were instructed to remember (working memory) one or three stimuli back (N-back) from the current stimulus on the screen while undergoing alternating periods of safety and threat of shock i.e. while anticipating unpleasant electric shocks or no shock (safe). Two levels of difficulties were tested: 1- and 3-back. The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually. Participants indicated whether the letter currently displayed was the same as the letter presented 1 or 3 letters back. The task included 3 runs, 8 blocks per run (4 safe and 4 threat presented alternatively), 18 sequential letters per block. Each block represented a given level of difficulty, i.e., 1- and 3-back. Performance on working memory task (n-back) accuracy was measured across condition (threat and safe) x Load (1-back, 3-back) using repeated measures ANOVA. (NCT02153944)
Timeframe: 90 minutes plus 90 seconds within a 6-hour study visit

InterventionProportion of correct responses (Mean)
fMRI: Drug Challenge With Methylphenidate0.9228125
fMRI: Drug Challenge With Placebo0.9378788

Proportion of Correct Responses in the Working Memory Task (N-back): Threat Condition - 1BACK - Run 2

Stimuli were presented one at a time on a screen. Participants were instructed to remember (working memory) one or three stimuli back (N-back) from the current stimulus on the screen while undergoing alternating periods of safety and threat of shock i.e. while anticipating unpleasant electric shocks or no shock (safe). Two levels of difficulties were tested: 1- and 3-back. The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually. Participants indicated whether the letter currently displayed was the same as the letter presented 1 or 3 letters back. The task included 3 runs, 8 blocks per run (4 safe and 4 threat presented alternatively), 18 sequential letters per block. Each block represented a given level of difficulty, i.e., 1- and 3-back. Performance on working memory task (n-back) accuracy was measured across condition (threat and safe) x Load (1-back, 3-back) using repeated measures ANOVA. (NCT02153944)
Timeframe: 90 minutes plus 260 seconds within a 6-hour study visit

InterventionProportion of correct responses (Mean)
fMRI: Drug Challenge With Methylphenidate0.9435484
fMRI: Drug Challenge With Placebo0.9425

Proportion of Correct Responses in the Working Memory Task (N-back): Threat Condition - 3BACK - Run 1

Stimuli were presented one at a time on a screen. Participants were instructed to remember (working memory) one or three stimuli back (N-back) from the current stimulus on the screen while undergoing alternating periods of safety and threat of shock i.e. while anticipating unpleasant electric shocks or no shock (safe). Two levels of difficulties were tested: 1- and 3-back. The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually. Participants indicated whether the letter currently displayed was the same as the letter presented 1 or 3 letters back. The task included 3 runs, 8 blocks per run (4 safe and 4 threat presented alternatively), 18 sequential letters per block. Each block represented a given level of difficulty, i.e., 1- and 3-back. Performance on working memory task (n-back) accuracy was measured across condition (threat and safe) x Load (1-back, 3-back) using repeated measures ANOVA. (NCT02153944)
Timeframe: 90 minutes plus 135 seconds within a 6-hour study visit

InterventionProportion of correct responses (Mean)
fMRI: Drug Challenge With Methylphenidate0.73
fMRI: Drug Challenge With Placebo0.7275758

Proportion of Correct Responses in the Working Memory Task (N-back): Threat Condition - 3BACK - Run 2

Stimuli were presented one at a time on a screen. Participants were instructed to remember (working memory) one or three stimuli back (N-back) from the current stimulus on the screen while undergoing alternating periods of safety and threat of shock i.e. while anticipating unpleasant electric shocks or no shock (safe). Two levels of difficulties were tested: 1- and 3-back. The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually. Participants indicated whether the letter currently displayed was the same as the letter presented 1 or 3 letters back. The task included 3 runs, 8 blocks per run (4 safe and 4 threat presented alternatively), 18 sequential letters per block. Each block represented a given level of difficulty, i.e., 1- and 3-back. Performance on working memory task (n-back) accuracy was measured across condition (threat and safe) x Load (1-back, 3-back) using repeated measures ANOVA. (NCT02153944)
Timeframe: 90 minutes plus 305 seconds within a 6-hour study visit

InterventionProportion of correct responses (Mean)
fMRI: Drug Challenge With Methylphenidate0.7816129
fMRI: Drug Challenge With Placebo0.7671875

Reaction Time to Stimuli: Safe Condition - 1BACK - Run 1

Reaction time (RT) is the time it takes to respond to stimuli. Participants RTs were measured while undergoing alternating periods of safety and shock threat conditions i.e. while anticipating unpleasant electric shocks (threat) or no shock (safe) during the n-back paradigm task. The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually. Two levels of difficulties were tested: 1Back and 3Back (n-back). Participants were instructed to indicate whether the letter currently displayed was the same as the letter presented 1 or 3 letters back. The task was organized in 2 runs, 8 blocks per run (4 safe and 4 threat presented alternatively), 18 sequential letters per block. Each block (threat or safe) corresponded to 2 tasks, 1- and 3-back tasks. RT was analyzed using condition( threat, safe) x Load (1Back, 3Back) repeated-measures ANOVA. (NCT02153944)
Timeframe: 90 minutes post drug admin plus zero seconds within a 6-hour study visit

Interventionmilliseconds (ms) (Mean)
fMRI: Drug Challenge With Methylphenidate743.283125
fMRI: Drug Challenge With Placebo794.7833333

Reaction Time to Stimuli: Safe Condition - 1BACK - Run 2

Reaction time (RT) is the time it takes to respond to stimuli. Participants RTs were measured while undergoing alternating periods of safety and shock threat conditions i.e. while anticipating unpleasant electric shocks (threat) or no shock (safe) during the n-back paradigm task. The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually. Two levels of difficulties were tested: 1Back and 3Back (n-back). Participants were instructed to indicate whether the letter currently displayed was the same as the letter presented 1 or 3 letters back. The task was organized in 2 runs, 8 blocks per run (4 safe and 4 threat presented alternatively), 18 sequential letters per block. Each block (threat or safe) corresponded to 2 tasks, 1- and 3-back tasks. RT was analyzed using condition (threat, safe) x Load (1Back, 3Back) repeated-measures ANOVA. (NCT02153944)
Timeframe: 90 minutes plus 180 seconds within a 6-hour study visit

Interventionmilliseconds (ms) (Mean)
fMRI: Drug Challenge With Methylphenidate707.7925806
fMRI: Drug Challenge With Placebo741.5425

Reaction Time to Stimuli: Safe Condition - 3BACK - Run 1

Reaction time (RT) is the time it takes to respond to stimuli. Participants RTs were measured while undergoing alternating periods of safety and shock threat conditions i.e. while anticipating unpleasant electric shocks (threat) or no shock (safe) during the n-back paradigm task. The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually. Two levels of difficulties were tested: 1Back and 3Back (n-back). Participants were instructed to indicate whether the letter currently displayed was the same as the letter presented 1 or 3 letters back. The task was organized in 2 runs, 8 blocks per run (4 safe and 4 threat presented alternatively), 18 sequential letters per block. Each block (threat or safe) corresponded to 2 tasks, 1- and 3-back tasks. RT was analyzed using condition (threat, safe) x Load (1Back, 3Back) repeated-measures ANOVA. (NCT02153944)
Timeframe: 90 minutes post drug admin plus 45 seconds within a 6-hour study visit

Interventionmilliseconds (ms) (Mean)
fMRI: Drug Challenge With Methylphenidate976.1853125
fMRI: Drug Challenge With Placebo1007.74

Reaction Time to Stimuli: Safe Condition - 3BACK - Run 2

Reaction time (RT) is the time it takes to respond to stimuli. Participants RTs were measured while undergoing alternating periods of safety and shock threat conditions i.e. while anticipating unpleasant electric shocks (threat) or no shock (safe) during the n-back paradigm task. The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually. Two levels of difficulties were tested: 1Back and 3Back (n-back). Participants were instructed to indicate whether the letter currently displayed was the same as the letter presented 1 or 3 letters back. The task was organized in 2 runs, 8 blocks per run (4 safe and 4 threat presented alternatively), 18 sequential letters per block. Each block (threat or safe) corresponded to 2 tasks, 1- and 3-back tasks. RT was analyzed using condition (threat, safe) x Load (1Back, 3Back) repeated-measures ANOVA. (NCT02153944)
Timeframe: 90 minutes plus 215 seconds within a 6-hour study visit

Interventionmilliseconds (ms) (Mean)
fMRI: Drug Challenge With Methylphenidate912.6574194
fMRI: Drug Challenge With Placebo915.005625

Reaction Time to Stimuli: Threat Condition - 1BACK - Run 1

Reaction time (RT) is the time it takes to respond to stimuli. Participants RTs were measured while undergoing alternating periods of safety and shock threat conditions i.e. while anticipating unpleasant electric shocks (threat) or no shock (safe) during the n-back paradigm task. The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually. Two levels of difficulties were tested: 1Back and 3Back (n-back). Participants were instructed to indicate whether the letter currently displayed was the same as the letter presented 1 or 3 letters back. The task was organized in 2 runs, 8 blocks per run (4 safe and 4 threat presented alternatively), 18 sequential letters per block. Each block (threat or safe) corresponded to 2 tasks, 1- and 3-back tasks. RT was analyzed using condition (threat, safe) x Load (1Back, 3Back) repeated-measures ANOVA. (NCT02153944)
Timeframe: 90 minutes plus 90 seconds within a 6-hour study visit

Interventionmilliseconds (ms) (Mean)
fMRI: Drug Challenge With Methylphenidate771.2671875
fMRI: Drug Challenge With Placebo779.1712121

Reaction Time to Stimuli: Threat Condition - 1BACK - Run 2

Reaction time (RT) is the time it takes to respond to stimuli. Participants RTs were measured while undergoing alternating periods of safety and shock threat conditions i.e. while anticipating unpleasant electric shocks (threat) or no shock (safe) during the n-back paradigm task. The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually. Two levels of difficulties were tested: 1Back and 3Back (n-back). Participants were instructed to indicate whether the letter currently displayed was the same as the letter presented 1 or 3 letters back. The task was organized in 2 runs, 8 blocks per run (4 safe and 4 threat presented alternatively), 18 sequential letters per block. Each block (threat or safe) corresponded to 2 tasks, 1- and 3-back tasks. RT was analyzed using condition (threat, safe) x Load (1Back, 3Back) repeated-measures ANOVA. (NCT02153944)
Timeframe: 90 minutes plus 260 seconds within a 6-hour study visit

Interventionmilliseconds (ms) (Mean)
fMRI: Drug Challenge With Methylphenidate729.0251613
fMRI: Drug Challenge With Placebo735.5509375

Reaction Time to Stimuli: Threat Condition - 3BACK - Run 1

Reaction time (RT) is the time it takes to respond to stimuli. Participants RTs were measured while undergoing alternating periods of safety and shock threat conditions i.e. while anticipating unpleasant electric shocks (threat) or no shock (safe) during the n-back paradigm task. The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually. Two levels of difficulties were tested: 1Back and 3Back (n-back). Participants were instructed to indicate whether the letter currently displayed was the same as the letter presented 1 or 3 letters back. The task was organized in 2 runs, 8 blocks per run (4 safe and 4 threat presented alternatively), 18 sequential letters per block. Each block (threat or safe) corresponded to 2 tasks, 1- and 3-back tasks. RT was analyzed using condition (threat, safe) x Load (1Back, 3Back) repeated-measures ANOVA. (NCT02153944)
Timeframe: 90 minutes plus 135 seconds within a 6-hour study visit

Interventionmilliseconds (ms) (Mean)
fMRI: Drug Challenge With Methylphenidate971.676875
fMRI: Drug Challenge With Placebo995.619697

Reaction Time to Stimuli: Threat Condition - 3BACK - Run 2

Reaction time (RT) is the time it takes to respond to stimuli. Participants RTs were measured while undergoing alternating periods of safety and shock threat conditions i.e. while anticipating unpleasant electric shocks (threat) or no shock (safe) during the n-back paradigm task. The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually. Two levels of difficulties were tested: 1Back and 3Back (n-back). Participants were instructed to indicate whether the letter currently displayed was the same as the letter presented 1 or 3 letters back. The task was organized in 2 runs, 8 blocks per run (4 safe and 4 threat presented alternatively), 18 sequential letters per block. Each block (threat or safe) corresponded to 2 tasks, 1- and 3-back tasks. RT was analyzed using condition (threat, safe) x Load (1Back, 3Back) repeated-measures ANOVA. (NCT02153944)
Timeframe: 90 minutes plus 305 seconds within a 6-hour study visit

Interventionmilliseconds (ms) (Mean)
fMRI: Drug Challenge With Methylphenidate925.3409677
fMRI: Drug Challenge With Placebo929.6796875

Magnitude of Startle Reflex During Safe Condition

"The magnitude of the startle reflex during working memory tasks (n-back) while undergoing alternating periods of safety and threat of shock. The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually. The participant holds each stimulus in short-term memory while new stimuli are presented. For each new item presented, the participant's task is to decide if it is the same as the stimulus presented one time before (1Back), two times before (2Back) or three times before (3Back) by responding yes if the stimulus currently presented matches the stimulus presented earlier. Participants responded with a button press. The startle reflex was elicited with a 102 decibel (dB) white noise (40-ms duration) delivered via headphone. The eyeblink component of the startle reflex was recorded binaurally with two silver chloride (AgCl) electrodes placed under one eye." (NCT02153944)
Timeframe: 20-120 milliseconds following the onset of the startle stimulus

,,
Interventionmillivolts (mV) (Mean)
1Back2Back3Back
Behavioral: Drug Challenge With Methylphenidate42.288089344.188640845.7608354
Behavioral: Drug Challenge With Placebo42.3980145.3298946.63108
Behavioral: Drug Challenge With Propranolol43.6124344.9669247.15858

Magnitude of Startle Reflex During Threat Condition

"The magnitude of the startle reflex during working memory tasks (n-back) while undergoing alternating periods of safety and threat of shock. The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually. The participant holds each stimulus in short-term memory while new stimuli are presented. For each new item presented, the participant's task is to decide if it is the same as the stimulus presented one time before (1Back), two times before (2Back) or three times before (3Back) by responding yes if the stimulus currently presented matches the stimulus presented earlier. Participants responded with a button press. The startle reflex was elicited with a 102 decibel (dB) white noise (40-ms duration) delivered via headphone. The eyeblink component of the startle reflex was recorded binaurally with two silver chloride (AgCl) electrodes placed under one eye." (NCT02153944)
Timeframe: 20-120 milliseconds following the onset of the startle stimulus

,,
Interventionmillivolts (mV) (Mean)
1Back2Back3Back
Behavioral: Drug Challenge With Methylphenidate51.681383351.095372552.1700802
Behavioral: Drug Challenge With Placebo51.7988251.6149251.40215
Behavioral: Drug Challenge With Propranolol52.2078350.1392950.53474

Measure of BOLD Response in Brain Cluster - Threat Condition - 1BACK

The blood-oxygen-level dependent (BOLD) responses were measured using an fMRI scanner. The cerebral fMRI BOLD uses magnetic fields to measure localized changes in brain blood flow and blood oxygenation in activated regions-of-interest (ROI). Participants BOLD responses were measured while undergoing alternating periods of safety and shock threat conditions i.e. while anticipating unpleasant electric shocks or no shock (safe) during the n-back task. The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually. Two levels of difficulties were tested: 1Back and 3Back (n-back). Participants were instructed to indicate whether the letter currently displayed was the same as the letter presented 1 or 3 letters back. (NCT02153944)
Timeframe: started 90 minutes post drug administration plus up to 360 seconds within a 6-hour study visit

,
Interventionarbitrary units (A.U) (Mean)
Brain Cluster-001 - Posterior Cingulate Cortex (PCC)Brain Cluster-002 - Right Prefrontal Cortex (PFC)Brain Cluster-003 - Left Prefrontal Cortex (PFC)Brain Cluster-004 - Anterior Cingulate Cortex (ACC)Brain Cluster-009 - Right PutamenBrain Cluster-11 - Frontal PoleBrain Cluster-12 - Right InsulaBrain Cluster-13 - Frontal PoleBrain Cluster-14-Right Insula
fMRI: Drug Challenge With Methylphenidate-0.1725431-0.0806112-0.1557721-0.1201138-0.06733-0.0929706-0.0543121-0.1420901-0.0580487
fMRI: Drug Challenge With Placebo-0.1488312-0.0609964-0.1297947-0.0940195-0.0435053-0.0173495-0.0434811-0.0822257-0.0542862

Measure of BOLD Response in Brain Cluster - Threat Condition - 3BACK

The blood-oxygen-level dependent (BOLD) responses were measured using an fMRI scanner. The cerebral fMRI BOLD uses magnetic fields to measure localized changes in brain blood flow and blood oxygenation in activated regions-of-interest (ROI). Participants BOLD responses were measured while undergoing alternating periods of safety and shock threat conditions i.e. while anticipating unpleasant electric shocks or no shock (safe) during the n-back task. The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually. Two levels of difficulties were tested: 1Back and 3Back (n-back). Participants were instructed to indicate whether the letter currently displayed was the same as the letter presented 1 or 3 letters back. (NCT02153944)
Timeframe: started 90 minutes post drug administration plus up to 450 seconds within a 6-hour study visit

,
Interventionarbitrary units (A.U) (Mean)
Brain Cluster-001 - Posterior Cingulate Cortex (PCC)Brain Cluster-002 - Right Prefrontal Cortex (PFC)Brain Cluster-003 - Left Prefrontal Cortex (PFC)Brain Cluster-004 - Anterior Cingulate Cortex (ACC)Brain Cluster-009 - Right PutamenBrain Cluster-11 - Frontal PoleBrain Cluster-12 - Right InsulaBrain Cluster-13 - Frontal PoleBrain Cluster-14-Right Insula
fMRI: Drug Challenge With Methylphenidate-0.0884053-0.0248587-0.0465762-0.089146-0.0470163-0.037367-0.0549414-0.1711822-0.0592526
fMRI: Drug Challenge With Placebo-0.1575204-0.0701165-0.0900214-0.1278046-0.0758935-0.022933-0.0925233-0.1896215-0.0882445

Measure of BOLD Response in Brain Clusters - Safe Condition - 1BACK

The blood-oxygen-level dependent (BOLD) responses were measured using an fMRI scanner. The cerebral fMRI BOLD uses magnetic fields to measure localized changes in brain blood flow and blood oxygenation in activated regions-of-interest (ROI). Participants BOLD responses were measured while undergoing alternating periods of safety and shock threat conditions i.e. while anticipating unpleasant electric shocks or no shock (safe) during the n-back task. The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually. Two levels of difficulties were tested: 1Back and 3Back (n-back). Participants were instructed to indicate whether the letter currently displayed was the same as the letter presented 1 or 3 letters back. (NCT02153944)
Timeframe: started 90 minutes post drug administration plus 90 seconds within a 6-hour study visit

,
Interventionarbitrary units (A.U) (Mean)
Brain Cluster-001 - Posterior Cingulate Cortex (PCC)Brain Cluster-002 - Right Prefrontal Cortex (PFC)Brain Cluster-003 - Left Prefrontal Cortex (PFC)Brain Cluster-004 - Anterior Cingulate Cortex (ACC)Brain Cluster-009 - Right PutamenBrain Cluster-11 - Frontal PoleBrain Cluster-12 - Right InsulaBrain Cluster-13 - Frontal PoleBrain Cluster-14 - Right Insula
fMRI: Drug Challenge With Methylphenidate-0.151002-0.0712797-0.1331336-0.1140823-0.0501889-0.0928793-0.0349776-0.1301602-0.0431302
fMRI: Drug Challenge With Placebo-0.2039758-0.1167484-0.1876725-0.151052-0.0848515-0.0743447-0.0830865-0.1309601-0.0856204

Measure of BOLD Response in Brain Clusters - Safe Condition - 3BACK

The blood-oxygen-level dependent (BOLD) responses were measured using an fMRI scanner. The cerebral fMRI BOLD uses magnetic fields to measure localized changes in brain The blood-oxygen-level dependent (BOLD) responses were measured using an fMRI scanner. The cerebral fMRI BOLD uses magnetic fields to measure localized changes in brain blood flow and blood oxygenation in activated regions-of-interest (ROI). Participants BOLD responses were measured while undergoing alternating periods of safety and shock threat conditions i.e. while anticipating unpleasant electric shocks or no shock (safe) during the n-back task. The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually. Two levels of difficulties were tested: 1Back and 3Back (n-back). Participants were instructed to indicate whether the letter currently displayed was the same as the letter presented 1 or 3 letters back. (NCT02153944)
Timeframe: started 90 minutes post drug administration plus up to 270 seconds within a 6-hour study visit

,
Interventionarbitrary units (A.U) (Mean)
Brain Cluster-001 - Posterior Cingulate Cortex (PCC)Brain Cluster-002 - Right Prefrontal Cortex (PFC)Brain Cluster-003 - Left Prefrontal Cortex (PFC)Brain Cluster-004 - Anterior Cingulate Cortex (ACC)Brain Cluster-009 - Right PutamenBrain Cluster-11 - Frontal PoleBrain Cluster-12 - Right InsulaBrain Cluster-13 - Frontal PoleBrain Cluster-14 - Right Insula
fMRI: Drug Challenge With Methylphenidate-0.1255616-0.0557781-0.0797764-0.1212111-0.0716675-0.0695188-0.0868275-0.2002039-0.0783793
fMRI: Drug Challenge With Placebo-0.1256943-0.0542905-0.0719455-0.1206337-0.05603060.001909-0.0971834-0.1695771-0.0832567

Measure of Heart Rate

The heart rate was monitored with two disposable electrodes on the ribcage midway between the waist and the armpit. (NCT02153944)
Timeframe: 20 minutes after arrival for study; 10 minutes & 145 minutes post drug administration

,
Interventionbeats/minute (Mean)
20 minutes after arrival for study10 minutes post drug administration145 minutes post drug administration
fMRI: Drug Challenge With Methylphenidate79.029411872.181818274.3030303
fMRI: Drug Challenge With Placebo77.294117672.647058869.7647059

Measure of Heart Rate

The heart rate was monitored with two disposable electrodes on the ribcage midway between the waist and the armpit. (NCT02153944)
Timeframe: 20 minutes after arrival for study; 80 minutes & 125 minutes post drug administration

,,
Interventionbeats/minute (Mean)
20 minutes after arrival for study80 minutes post drug administration125 minutes post drug administration
Behavioral: Drug Challenge With Methylphenidate72.873.675.75
Behavioral: Drug Challenge With Placebo74.3575.172.45
Behavioral: Drug Challenge With Propranolol66.3564.660.05

Measure of Level of Anxiety

"The level of anxiety was assessed using the State Anxiety Inventory questionnaire. The State Anxiety Scale (S-Anxiety) evaluates the current state of anxiety. The State Anxiety Scale has 20 items. All items are rated on a 4-point scale ranging from 1 = not at all to 4 = very much so. The scale has a minimum score of 20 and a maximum score of 80. Higher score indicates greater anxiety. State Anxiety score was measured at different time points during the study." (NCT02153944)
Timeframe: 20 minutes after arrival for study; 10 minutes & 145 minutes post drug administration

,
InterventionUnits on a scale (Mean)
20 minutes after arrival for study10 minutes post drug administration145 minutes post drug administration
fMRI: Drug Challenge With Methylphenidate24.636363627.235294132.4705882
fMRI: Drug Challenge With Placebo23.181818224.235294129.6969697

Measure of Level of Anxiety

"The level of anxiety was assessed using the State Anxiety Inventory questionnaire. The State Anxiety Scale (S-Anxiety) evaluates the current state of anxiety. The State Anxiety Scale has 20 items. All items are rated on a 4-point scale ranging from 1 = not at all to 4 = very much so. The scale has a minimum score of 20 and a maximum score of 80. Higher score indicates greater anxiety. State Anxiety score was measured at different time points during the study." (NCT02153944)
Timeframe: 20 minutes after arrival for study; 80, 100, & 125 minutes post drug administration

,,
InterventionUnits on a scale (Mean)
20 minutes after arrival for study80 minutes post drug administration100 minutes post drug administration125 minutes post drug administration
Behavioral: Drug Challenge With Methylphenidate26.3525.7536.434.15
Behavioral: Drug Challenge With Placebo25.725.536.233.25
Behavioral: Drug Challenge With Propranolol27.6528.337.934.31579

Proportion of Correct Responses in the Working Memory Task (N-back) - Safe Condition

"Stimuli were presented one at a time on a screen. Participants were instructed to remember (working memory) one, two, or three stimuli back (N-back) from the current stimulus on the screen while undergoing alternating periods of safety and threat of shock i.e. while anticipating unpleasant electric shocks or no shock (safe). The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually. The participant holds each stimulus in short-term memory while new stimuli are presented. For each new item presented, the participant's task is to decide if it is the same as the stimulus presented one time before (1Back), two times before (2Back) or three times before (3Back) by responding yes if the stimulus currently presented matches the stimulus presented earlier. Performance on working memory task (n-back) accuracy was measured across condition (threat and safe) x Load (1Back, 2Back, 3Back) using repeated measures ANOVA." (NCT02153944)
Timeframe: Task started 90 minutes post drug admin up to max of 125 mins post drug admin (max total is 35 mins) during a 6-hour single day visit

,,
InterventionProportion of correct responses (Mean)
1Back2Back3Back
Behavioral: Drug Challenge With Methylphenidate0.962350.925850.82115
Behavioral: Drug Challenge With Placebo0.92850.87340.792
Behavioral: Drug Challenge With Propranolol0.945350.90390.8528

Proportion of Correct Responses in the Working Memory Task (N-back) - Threat Condition

"Stimuli were presented one at a time on a screen. Participants were instructed to remember (working memory) one, two, or three stimuli back (N-back) from the current stimulus on the screen while undergoing alternating periods of safety and threat of shock i.e. while anticipating unpleasant electric shocks or no shock (safe). The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually. The participant holds each stimulus in short-term memory while new stimuli are presented. For each new item presented, the participant's task is to decide if it is the same as the stimulus presented one time before (1Back), two times before (2Back) or three times before (3Back) by responding yes if the stimulus currently presented matches the stimulus presented earlier. Performance on working memory task (n-back) accuracy was measured across condition (threat and safe) x Load (1Back, 2Back, 3Back) using repeated measures ANOVA." (NCT02153944)
Timeframe: task started 90 minutes post drug admin up to max of 125 mins post drug admin (max total is 35 mins) during a 6-hour single day visit

,,
InterventionProportion of correct responses (Mean)
1Back2Back3Back
Behavioral: Drug Challenge With Methylphenidate0.95860.885050.8358
Behavioral: Drug Challenge With Placebo0.927550.832550.74575
Behavioral: Drug Challenge With Propranolol0.944450.882750.8152

Change From DB Baseline in Conners' Adult ADHD Rating Scale (CAARS) Total Score at DB Endpoint

"To evaluate maintenance of treatment effects of PR OROS MPH vs. placebo as measured on CAARS.~CAARS assesses ADHD symptoms and behaviors in adults. best value: 0 worst value: 54~Endpoint: last available post-baseline assessment." (NCT00307684)
Timeframe: DB baseline, DB endpoint

Interventionunits on a scale (Mean)
Active4.0
Placebo6.5

Change From DB Baseline to DB Endpoint in CAARS Self Rated Scale (CAARS-S:S) Total Score

Evaluation of treatment effects as rated by the subjects on the CAARS-S:S. best score: 0 worst score: 104 (NCT00307684)
Timeframe: DB baseline, DB endpoint

Interventionunits on a scale (Mean)
Active4.4
Placebo4.0

Change From DB Baseline to DB Endpoint in CGI-S Score

evaluation of treatment effects as rated by the investigator on the CGI-S scale. CGI-S is used to rate the severity of a subject's illness on a 7- point scale ranging from 1 (not ill) to 7 (extremely severe). (NCT00307684)
Timeframe: DB baseline, DB endpoint

Interventionunits on a scale (Mean)
Active0.6
Placebo1.0

Change From OL Baseline in Clinical Global Impression Scale (CGI-S) Score at OL Endpoint

Assessment of the long term effect on overall functioning measured by CGI-S best score: 1 worst score: 7 (NCT00307684)
Timeframe: OL baseline, OL endpoint

Interventionunits on a scale (Mean)
Open Label PR OROS MPH-0.3

Change From OL Baseline in Quality of Life, Enjoyment and Satisfaction Questionnaire (Q-LES-Q) Score at OL Endpoint

Quality of life measured by Q-LES-Q best score: 100 worst score: 0 (NCT00307684)
Timeframe: OL baseline, OL endpoint

Interventionunits on a scale (Mean)
Open Label PR OROS MPH1.4

Change From OL Baseline to OL Endpoint in Conners' Adult ADHD Rating Scale (CAARS) Total and Subscale Scores

"Long term efficacy of PR OROS MPH as assessed by investigator-rated CAARS total score, hyperactivity/impulsivity subscale score and inattention subscale score.~Subscale scores: best value: 0, worst value: 27" (NCT00307684)
Timeframe: OL baseline, OL endpoint

Interventionunits on a scale (Mean)
change from baseline to endpoint in total scorechange from baseline to endpoint in inattentionchange from baseline to endpoint in hyperactivity
Open Label PR OROS MPH-1.9-1.0-0.9

Frequency of Adverse Events (AEs) and Serious Adverse Events (SAEs)

To evaluate the long term safety and tolerability of PR OROS MPH (18, 36, 54, 72 and 90 mg/day) in adults with Attention Deficit Hyperactivity Disorder (ADHD) (NCT00307684)
Timeframe: Treatment duration for OL extended from 52 wks to 72 wks (International Amendment 2) or 108 wks in Germany. Treatment duration for double-blind (DB) randomized withdrawal: 4 weeks

,,
Interventionparticipants (Number)
at least one AEat least one SAEat least one severe AEat least one AE leading to permanent stopat least one AE leading to temporary stopat least one AE with concomitant therapyat least one AE at least possibly related
Active7000003
Open Label PR OROS MPH126122715239362
Placebo8130245

Change From Extension Baseline (Week 40) to End of Study (Week 66) in on DSM-IV Attention-Deficit/Hyperactivity Disorder Rating Scale (DSM-IV ADHD RS) Total Score.

"Attention-Deficit/Hyperactivity Disorder Rating Scale (DSM-IV ADHD RS) total score consists of 18 items directly adapted from the ADHD symptom list according to the DSM-IV. The DSM-IV ADHD RS total score was calculated as the sum of the Inattentive and the Hyperactive-Impulsive subscores. The 18 items are rated from 0 (rarely or never) to 3 (Very often). The total score ranges from 0 to 54. Decrease in the DSM-IV ADHD RS total score indicates improvement, therefore a greater decrease (change at Final Visit compared to baseline) indicates a greater improvement in ADHD symptoms. Last Observation Carried Forward (LOCF) applied for each patient with data in extension period. If no post-baseline is available, it is considered as missing." (NCT01338818)
Timeframe: week 40 - week 66

Interventionscores on a scale (Mean)
Ritalin LA-7.2

Change From Extension Baseline (Week 40) to End of Study (Week 66) on Sheehan Disability Scale (SDS) Total Score

SDS,5-self-rated questionnaire to measure the extent a pt's disability due to an illness/health problem interferes with work/school,social life/leisure,family life/home. First 3 items, pts are asked how their symptoms disrupted their regular activities over the past 7d in each using a scale from 0(not at all)-10(extremely) Each subscale(work disability, social life disability, family life disability)can be scored independently or combined into a total score(sum of the non-missing responses for items 1-3)from 0-30,higher scores indicate significant functional impairment. Subscale scores>5 suggest impairment in that subscale area. Final 2 items ask pts about the # of days their symptoms caused them to miss school/work and # of days their symptoms caused them to be underproductive at school/work.(These items were not included in the total score.) Before responding to SDS items 1-3, pts were verbally instructed to recall the past 7d, items 4-5 refer to the last week w/in the item wording. (NCT01338818)
Timeframe: week 40 - week 66

InterventionScores on a scale (Mean)
Ritalin LA-4.8

Number of Participants With Adverse Events, Serious Adverse Events and Deaths.

Adverse Events, Serious Adverse Events and Deaths were monitored from week 40 to week 66. (NCT01338818)
Timeframe: Week 40 - Week 66

Interventionparticipants (Number)
Adverse Events (Serious and Non Serious)Serious Adverse EventsDeaths
Ritalin LA20820

Difference in Time Sensitive ADHD Symptom Scale (TASS) Between Treatment Groups to Establish Non-inferiority

TASS was completed at the end of waking hours (14 - 16 hours post-dosing) at Month-2 after baseline visit. TASS was developed to capture the change in ADHD symptoms over the course of a day and consists of 18 items that directly correspond to the 18 ADHD symptom domains listed in the DSM-5. Each item is scored on a 4-point scale as follows: 0 (none), 1 (mild), 2 (moderate), and 3 (severe); the maximum total score is 54. A higher total score corresponds to worse ADHD severity. (NCT04507204)
Timeframe: Month-2

Interventionscore on a scale (Least Squares Mean)
Adhansia XR20.2
Concerta22.1

Adult ADHD Quality of Life Scale - Revised (AAQoL-R)

Used to assess health-related quality of life for adult patients. The AAQoL yields a total score based on 29 items. The raw scores are transformed to a 0 to 100 scale with higher scores indicating a better quality of life. (NCT04507204)
Timeframe: Baseline, Months -1, -2, -3, -4, -5 and -6

,
Interventionscore on a scale (Least Squares Mean)
Total Score at BaselineTotal Score at Month 1Total Score at Month 2Total Score at Month 3Total Score at Month 4Total Score at Month 5Total Score at Month 6
Adhansia XR41.155.563.063.464.766.367.4
Concerta41.155.059.160.961.860.263.6

Assessment of Clinical Global Impression-Improvement (CGI-I)

The CGI-I measures global improvement prior to and after initiating the study medication. The CGI-I scale is 1 question, and rates improvement compared with the baseline visit using a 7-point scale. The range of responses are from 1 (very much improved) through 7 (very much worse). A higher score corresponds to higher ADHD severity. (NCT04507204)
Timeframe: Month-2, Month-4, and Month-6

,
Interventionscore on a scale (Least Squares Mean)
Month 2Month 4Month 6
Adhansia XR2.32.02.0
Concerta2.32.22.3

Assessment of Clinical Global Impression-Severity (CGI-S)

The CGI-S rates symptoms from 1 (not ill) to 7 (extremely ill). A higher score corresponds to higher ADHD severity. (NCT04507204)
Timeframe: Baseline, Month-2, Month-4, and Month-6

,
Interventionscore on a scale (Least Squares Mean)
BaselineMonth 2Month 4Month 6
Adhansia XR4.63.12.72.7
Concerta4.63.23.03.1

Assessment of Treatment Satisfaction

"The Treatment Satisfaction Questionnaire for Medications (TSQM) measures a patient's level of satisfaction or dissatisfaction with the study medication. It assesses perceptions of effectiveness, side effects and convenience of the medication and consists of 14 items that evaluate these three domains and one global scale item (ie, global satisfaction). Scores for each domain are computed by adding the TSQM items in each domain and then transforming the composite score into a value ranging from 0 to 100.~A lower score indicates a lower satisfaction with treatment." (NCT04507204)
Timeframe: Month-1, Month-2, and Month-6

,
Interventionscore on a scale (Least Squares Mean)
Global Satisfaction at Month 1Global Satisfaction at Month 2Global Satisfaction at Month 6Effectiveness at Month 1Effectiveness at Month 2Effectiveness at Month 6Side Effects at Month 1Side Effects at Month 2Side Effects at Month 6Convenience at Month 1Convenience at Month 2Convenience at Month 6
Adhansia XR84.885.286.251.361.163.974.072.070.758.957.059.7
Concerta84.382.884.352.458.861.969.667.674.159.258.757.0

Change in ADHD-Rating Scale 5 (ADHD-RS-5) Total Score From Baseline to Month 2 Among Patients Treated With Adhansia XR

The ADHD-RS-5 assesses the frequency and severity of each of the 18 ADHD symptoms among adults based on DSM-5 criteria. Each of the 18 DSM-5 symptoms are rated on a 4 point scale from 0 (never or rarely) to 3 (very often), yielding a total score of 0 to 54. A higher score corresponds to worse ADHD severity. (NCT04507204)
Timeframe: Baseline to Month-2

Interventionscore on a scale (Mean)
Total Score at baselineTotal Score at Month 2
Adhansia XR34.618.7

Healthcare Resource Utilization (HCRU)

A comparison of the frequency of health care encounters between the 2 treatment groups. Healthcare resource utilization were evaluated monthly by comparing the frequency of clinic visits (outpatient), inpatient/hospitalizations (and length of stay), and emergency department visits between the 2 treatment groups. (NCT04507204)
Timeframe: Baseline (past 6 months) Months -2, -4, and -6

,
InterventionVisits or Inpatient Admissions (Least Squares Mean)
Baseline (past 6 months) Overall Total Visits or Inpatient AdmissionsMonth 2 - Overall Total Visits or Inpatient AdmissionsMonth 4 - Overall Total Visits or Inpatient AdmissionsMonth 6 - Overall Total Visits or Inpatient Admissions
Adhansia XR2.142.261.671.34
Concerta2.932.431.731.85

Patient Sleep Quality as Measured by the Pittsburgh Sleep Quality Index (PSQI)

"The PSQI is an instrument used to measure the quality and patterns of sleep; It differentiates poor from good sleep. It is filled out by the caregiver or the patient and the global sum score ranges from 0 to 21, with higher scores indicating worse sleep quality." (NCT04507204)
Timeframe: Baseline and Months -2, -4, and -6

,
Interventionscore on a scale (Least Squares Mean)
Global PSQI - BaselineGlobal PSQI - Month 2Global PSQI - Month 4Global PSQI - Month 6
Adhansia XR9.687.928.117.92
Concerta9.599.597.767.80

Work Productivity and Activity Impairment (WPAI) Questionnaire

The WPAI questionnaire is designed to measure the effect of general health and symptom severity on work productivity and regular activities during the past 7 days. It consists of 4 domains [absenteeism (missing work), presenteeism (impaired productivity at work), overall work performance (combined absenteeism and presenteeism), and non-work activities (activity impairment)]. WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity. (NCT04507204)
Timeframe: Baseline, Months -2, -3, -4, -5, and -6

,
Interventionpercentage of impairment (Least Squares Mean)
Percent work time missed due to health (Absenteeism) - BaselinePercent work time missed due to health (Absenteeism) - Month 2Percent work time missed due to health (Absenteeism) - Month 3Percent work time missed due to health (Absenteeism) - Month 4Percent work time missed due to health (Absenteeism) - Month 5Percent work time missed due to health (Absenteeism) - Month 6Percent impairment while working due to health (Presenteeism) - BaselinePercent impairment while working due to health (Presenteeism) - Month 2Percent impairment while working due to health (Presenteeism) - Month 3Percent impairment while working due to health (Presenteeism) - Month 4Percent impairment while working due to health (Presenteeism) - Month 5Percent impairment while working due to health (Presenteeism) - Month 6Percent overall work impairment due to health - BaselinePercent overall work impairment due to health - Month 2Percent overall work impairment due to health - Month 3Percent overall work impairment due to health - Month 4Percent overall work impairment due to health - Month 5Percent overall work impairment due to health - Month 6Percent activity impairment due to health - BaselinePercent activity impairment due to health - Month 2Percent activity impairment due to health - Month 3Percent activity impairment due to health - Month 4Percent activity impairment due to health - Month 5Percent activity impairment due to health - Month 6
Adhansia XR5.44.23.02.44.82.932.019.720.113.517.815.934.122.421.815.819.718.439.726.126.119.523.621.9
Concerta5.63.73.24.74.94.133.324.225.024.618.317.635.527.226.425.319.518.940.930.127.128.626.323.5

Reviews

7 reviews available for methylphenidate and Anxiety Neuroses

ArticleYear
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    The Cochrane database of systematic reviews, 2022, Feb-24, Volume: 2

    Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim

2022
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    The Cochrane database of systematic reviews, 2022, Feb-24, Volume: 2

    Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim

2022
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    The Cochrane database of systematic reviews, 2022, Feb-24, Volume: 2

    Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim

2022
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    The Cochrane database of systematic reviews, 2022, Feb-24, Volume: 2

    Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim

2022
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    The Cochrane database of systematic reviews, 2022, Feb-24, Volume: 2

    Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim

2022
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    The Cochrane database of systematic reviews, 2022, Feb-24, Volume: 2

    Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim

2022
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    The Cochrane database of systematic reviews, 2022, Feb-24, Volume: 2

    Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim

2022
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    The Cochrane database of systematic reviews, 2022, Feb-24, Volume: 2

    Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim

2022
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    The Cochrane database of systematic reviews, 2022, Feb-24, Volume: 2

    Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim

2022
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    The Cochrane database of systematic reviews, 2022, Feb-24, Volume: 2

    Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim

2022
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    The Cochrane database of systematic reviews, 2022, Feb-24, Volume: 2

    Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim

2022
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    The Cochrane database of systematic reviews, 2022, Feb-24, Volume: 2

    Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim

2022
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    The Cochrane database of systematic reviews, 2022, Feb-24, Volume: 2

    Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim

2022
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    The Cochrane database of systematic reviews, 2022, Feb-24, Volume: 2

    Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim

2022
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    The Cochrane database of systematic reviews, 2022, Feb-24, Volume: 2

    Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim

2022
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    The Cochrane database of systematic reviews, 2022, Feb-24, Volume: 2

    Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim

2022
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    The Cochrane database of systematic reviews, 2022, Feb-24, Volume: 2

    Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim

2022
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    The Cochrane database of systematic reviews, 2022, Feb-24, Volume: 2

    Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim

2022
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    The Cochrane database of systematic reviews, 2022, Feb-24, Volume: 2

    Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim

2022
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    The Cochrane database of systematic reviews, 2022, Feb-24, Volume: 2

    Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim

2022
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    The Cochrane database of systematic reviews, 2022, Feb-24, Volume: 2

    Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim

2022
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    The Cochrane database of systematic reviews, 2022, Feb-24, Volume: 2

    Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim

2022
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    The Cochrane database of systematic reviews, 2022, Feb-24, Volume: 2

    Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim

2022
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    The Cochrane database of systematic reviews, 2022, Feb-24, Volume: 2

    Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim

2022
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    The Cochrane database of systematic reviews, 2022, Feb-24, Volume: 2

    Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim

2022
Pharmacological treatment of attention-deficit hyperactivity disorder comorbid with an anxiety disorder: a systematic review.
    International clinical psychopharmacology, 2019, Volume: 34, Issue:2

    Topics: Adolescent; Adult; Anxiety Disorders; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyp

2019
Optimizing outcomes in ADHD treatment: from clinical targets to novel delivery systems.
    CNS spectrums, 2016, Volume: 21, Issue:S1

    Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic Uptake Inhibitors; Anxiety Disorders; Atomoxetine H

2016
[Use of psychotropic drugs in children].
    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2008, Volume: 15, Issue:12

    Topics: Adolescent; Age Factors; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Anxiety Dis

2008
[Effects of methylphenidate on anxiety].
    Revista de neurologia, 2012, Oct-16, Volume: 55, Issue:8

    Topics: Adolescent; Adult; Age Factors; Animals; Anti-Anxiety Agents; Anxiety; Anxiety Disorders; Attention

2012
Depression and dysphoria effects on the interpersonal perception of negative and positive moods and caring relationships: effects of antidepressants, amphetamine, and methylphenidate.
    Current psychiatry reports, 2003, Volume: 5, Issue:6

    Topics: Amphetamine; Antidepressive Agents; Anxiety Disorders; Central Nervous System Stimulants; Clinical T

2003
[Conduct disorder, unsocialized and socialized].
    Ryoikibetsu shokogun shirizu, 2003, Issue:40

    Topics: Antipsychotic Agents; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nerv

2003

Trials

16 trials available for methylphenidate and Anxiety Neuroses

ArticleYear
Methylphenidate modulates interactions of anxiety with cognition.
    Translational psychiatry, 2021, 10-21, Volume: 11, Issue:1

    Topics: Adult; Anxiety; Anxiety Disorders; Cognition; Humans; Memory, Short-Term; Methylphenidate

2021
The effects of Psychotropic drugs On Developing brain (ePOD) study: methods and design.
    BMC psychiatry, 2014, Feb-19, Volume: 14

    Topics: Adolescent; Adult; Animals; Antidepressive Agents; Anxiety Disorders; Attention Deficit Disorder wit

2014
Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial.
    The American journal of psychiatry, 2015, Volume: 172, Issue:6

    Topics: Aged; Anxiety Disorders; Apathy; Citalopram; Cognition Disorders; Depressive Disorder, Major; Double

2015
A possible effect of methylphenidate on state anxiety: A single dose, placebo controlled, crossover study in a control group.
    Psychiatry research, 2016, Jul-30, Volume: 241

    Topics: Adult; Anxiety Disorders; Attention; Central Nervous System Stimulants; Control Groups; Cross-Over S

2016
Depression, anxiety and obsessive-compulsive symptoms and quality of life in children with attention-deficit hyperactivity disorder (ADHD) during three-month methylphenidate treatment.
    Journal of psychopharmacology (Oxford, England), 2010, Volume: 24, Issue:12

    Topics: Adolescent; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System

2010
Methylphenidate and comorbid anxiety disorder in children with both chronic multiple tic disorder and ADHD.
    Journal of attention disorders, 2011, Volume: 15, Issue:3

    Topics: Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants;

2011
Clinical response to methylphenidate in children diagnosed with attention-deficit hyperactivity disorder and comorbid psychiatric disorders.
    Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2010, Volume: 55, Issue:5

    Topics: Anxiety Disorders; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder w

2010
A multicenter, open-label trial to evaluate the quality of life in adults with ADHD treated with long-acting methylphenidate (OROS MPH): Concerta Quality of Life (CONQoL) study.
    Journal of attention disorders, 2013, Volume: 17, Issue:5

    Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Brazil; Central Nervous Sys

2013
Sequential pharmacotherapy for children with comorbid attention-deficit/hyperactivity and anxiety disorders.
    Journal of the American Academy of Child and Adolescent Psychiatry, 2005, Volume: 44, Issue:5

    Topics: Adolescent; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System

2005
Clinical presentation of attention-deficit/hyperactivity disorder in preschool children: the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS).
    Journal of child and adolescent psychopharmacology, 2007, Volume: 17, Issue:5

    Topics: Anxiety Disorders; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder w

2007
Anxiety, methylphenidate response, and working memory in children with ADHD.
    Journal of attention disorders, 2008, Volume: 11, Issue:5

    Topics: Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants;

2008
Differential effects of methylphenidate on working memory in ADHD children with and without comorbid anxiety.
    Journal of the American Academy of Child and Adolescent Psychiatry, 1995, Volume: 34, Issue:7

    Topics: Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Child; Comorbidity; Dose-Response

1995
A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder.
    Archives of general psychiatry, 1995, Volume: 52, Issue:6

    Topics: Adolescent; Adult; Age Factors; Ambulatory Care; Anxiety Disorders; Attention Deficit Disorder with

1995
Response to methylphenidate in children with ADHD and comorbid anxiety.
    Journal of the American Academy of Child and Adolescent Psychiatry, 1999, Volume: 38, Issue:4

    Topics: Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants;

1999
A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD.
    Archives of general psychiatry, 1999, Volume: 56, Issue:12

    Topics: Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous

1999
A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD.
    Archives of general psychiatry, 1999, Volume: 56, Issue:12

    Topics: Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous

1999
A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD.
    Archives of general psychiatry, 1999, Volume: 56, Issue:12

    Topics: Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous

1999
A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD.
    Archives of general psychiatry, 1999, Volume: 56, Issue:12

    Topics: Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous

1999
Effect of anxiety on cognition, behavior, and stimulant response in ADHD.
    Journal of the American Academy of Child and Adolescent Psychiatry, 1989, Volume: 28, Issue:6

    Topics: Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Child; Child Behavior Disorders; D

1989

Other Studies

22 other studies available for methylphenidate and Anxiety Neuroses

ArticleYear
Prolonged Postconcussive Symptoms.
    The American journal of psychiatry, 2018, 02-01, Volume: 175, Issue:2

    Topics: Accidents, Traffic; Adaptation, Psychological; Anxiety Disorders; Attention; Axons; Brain Concussion

2018
Resolution of Anxiety Symptoms in Response to Stimulants in a Patient With Attention-Deficit/Hyperactivity Disorder and Generalized Anxiety Disorder.
    The primary care companion for CNS disorders, 2018, May-31, Volume: 20, Issue:3

    Topics: Adult; Amphetamine; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervou

2018
Childhood narcolepsy and autism spectrum disorders: four case reports.
    Sleep medicine, 2018, Volume: 51

    Topics: Age of Onset; Antidepressive Agents; Anxiety Disorders; Asperger Syndrome; Attention Deficit Disorde

2018
Treatment of Comorbid Adult Attention-deficit/Hyperactivity Disorder and Generalized Anxiety Disorder: 2 Case Reports.
    Journal of psychiatric practice, 2018, Volume: 24, Issue:4

    Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim

2018
Methylphenidate Reduces State Anxiety During a Continuous Performance Test That Distinguishes Adult ADHD Patients From Controls.
    Journal of attention disorders, 2017, Volume: 21, Issue:1

    Topics: Adult; Analysis of Variance; Anxiety; Anxiety Disorders; Attention; Attention Deficit Disorder with

2017
Psychiatric Comorbidity at the Time of Diagnosis in Adults With ADHD: The CAT Study.
    Journal of attention disorders, 2016, Volume: 20, Issue:12

    Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Comorbidity; Cross-Sectiona

2016
Prevalence, Patient Characteristics, and Pharmacological Treatment of Children, Adolescents, and Adults Diagnosed With ADHD in Sweden.
    Journal of attention disorders, 2018, Volume: 22, Issue:1

    Topics: Adolescent; Adult; Age Distribution; Anxiety Disorders; Attention Deficit Disorder with Hyperactivit

2018
Response to methylphenidate in children and adolescents with ADHD: does comorbid anxiety disorders matters?
    Journal of neural transmission (Vienna, Austria : 1996), 2009, Volume: 116, Issue:5

    Topics: Adolescent; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Brain; Causality; Cent

2009
Increased glutamate-stimulated release of dopamine in substantia nigra of a rat model for attention-deficit/hyperactivity disorder--lack of effect of methylphenidate.
    Metabolic brain disease, 2009, Volume: 24, Issue:4

    Topics: Action Potentials; Animals; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Diseas

2009
Evaluation of light/dark cycle in anxiety- and depressive-like behaviors after regular treatment with methylphenidate hydrochloride in rats of different ages.
    Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), 2011, Volume: 33, Issue:1

    Topics: Age Factors; Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety Disorders; Attention Defic

2011
Stimulant adherence and academic performance in urban youth with attention-deficit/hyperactivity disorder.
    Journal of the American Academy of Child and Adolescent Psychiatry, 2011, Volume: 50, Issue:5

    Topics: Achievement; Adolescent; Amphetamine; Anxiety Disorders; Attention Deficit and Disruptive Behavior D

2011
[Attention deficit disorder: multidisciplinary observational study over 1 year].
    L'Encephale, 2011, Volume: 37, Issue:3

    Topics: Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants;

2011
Dexamphetamine for obsessive-compulsive disorder.
    The American journal of psychiatry, 2003, Volume: 160, Issue:1

    Topics: Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants;

2003
Methylphenidate-induced obsessive-compulsive symptoms in an elderly man.
    CNS spectrums, 2003, Volume: 8, Issue:8

    Topics: Aged; Aged, 80 and over; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety Diso

2003
[Considerations on the use of reserpine & phenyl (alpha-piperidyl) acetic acid in the treatment of preoperative anxiety states].
    Rivista di ostetricia e ginecologia, 1957, Volume: 12, Issue:3

    Topics: Acetates; Acetic Acid; Anxiety; Anxiety Disorders; Humans; Methylphenidate; Preoperative Care; Reser

1957
THE TREATMENT OF ANXIETY WITH LYSERGIC ACID AND METHYL PHENIDATE.
    The Practitioner, 1963, Volume: 191

    Topics: Anxiety; Anxiety Disorders; Humans; Lysergic Acid; Lysergic Acid Diethylamide; Methylphenidate; Neur

1963
MODIFICATIONS IN THE TECHNIQUE OF LSD THERAPY.
    Comprehensive psychiatry, 1964, Volume: 5

    Topics: Anxiety; Anxiety Disorders; Brain Chemistry; Drug Therapy; Drug Tolerance; Hospital Design and Const

1964
Treating adolescent girls and women with ADHD: gender-specific issues.
    Journal of clinical psychology, 2005, Volume: 61, Issue:5

    Topics: Adolescent; Adult; Age Factors; Amphetamine; Anxiety Disorders; Attention Deficit Disorder with Hype

2005
Clinical experience of the use of a pharmacological treatment algorithm for major depressive disorder in patients with advanced cancer.
    Psycho-oncology, 2008, Volume: 17, Issue:2

    Topics: Adult; Aged; Algorithms; Alprazolam; Amitriptyline; Antidepressive Agents; Anxiety Disorders; Benzod

2008
[Psychotropic drugs for children].
    MMW, Munchener medizinische Wochenschrift, 1981, Feb-13, Volume: 123, Issue:7

    Topics: Amitriptyline; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Benzodiazepines; Ce

1981
Combined pharmacotherapy: an emerging trend in pediatric psychopharmacology.
    Journal of the American Academy of Child and Adolescent Psychiatry, 1995, Volume: 34, Issue:1

    Topics: Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Benzodiazepines; Child Psychiatry;

1995
[The influence of the sequence in cross over trials].
    Activitas nervosa superior, 1968, Oct-03, Volume: 10, Issue:3

    Topics: Anxiety Disorders; Chlordiazepoxide; Diazepam; Hospitalization; Humans; Methylphenidate; Placebos

1968